GPT 4o answer:
Switching from a ventricular-only leadless pacemaker (like the Abbott Aveir VR) to one that provides conduction system pacing (CSP) — such as the investigational Aveir CSP — is a significant decision and depends on several clinical, physiological, and technological factors.
Here's a breakdown to guide the decision:
Unstable thresholds = higher output requirements
If thresholds are unstable at night, especially increasing to >3.0 V @ 0.4 ms, the device will need to deliver more energy — reducing battery life and potentially increasing myocardial fibrosis due to high-voltage stimulation.
Long-term pacing dependency
If you're relatively young or expected to rely on the pacemaker for many years, switching early to a more physiologic pacing strategy like CSP could protect long-term ventricular function.
Conduction system pacing preserves synchrony
CSP mimics natural electrical conduction via the His-Purkinje system, which may reduce risks of pacing-induced cardiomyopathy compared to right ventricular pacing.
Future-proofing
If battery longevity, fibrosis, or progressive threshold issues are forecasted to become problematic, transitioning earlier — especially before symptoms or complications arise — might avoid a more complex reintervention later.
No symptoms
If you're asymptomatic despite nocturnal threshold instability, it might not yet justify the risks of a new invasive procedure, especially given the still investigational status of leadless CSP systems.
Nighttime vagal influence might be manageable
High vagal tone during sleep may temporarily elevate capture thresholds. This can sometimes be managed conservatively (e.g., adjusting body position, tweaking rate-response features, or considering autonomic-modulating strategies).
CSP is not yet FDA-approved
Leadless CSP is still in clinical trials (e.g., Abbott’s ASCEND-CSP). Switching now would be off-label or part of a trial, limiting widespread access and long-term data.
Device replacement risks
Any explant and reimplant procedure carries procedural risks — especially if the current device still functions acceptably.
How often and how severely is capture failing?
Are there early signs of battery drain?
Are nighttime non-captures due to reversible autonomic factors?
Is CSP technology available in your country/hospital?
Are you willing to enroll in a clinical trial (e.g., ASCEND-CSP)?
If no symptoms are present, battery longevity is acceptable, and threshold instability is only nocturnal and possibly vagally mediated — then close monitoring, device optimization, and conservative management would likely be preferred until more data becomes available or symptoms arise.
But if you are pacing-dependent, showing signs of increasing fibrosis, or anticipate long-term high-output needs, CSP could offer a more physiological and sustainable alternative.
Would you like to explore how autonomic tone modulation or positional adjustments might help your current situation without changing devices?